Previous clinical studies among HFrEF patients have revealed that different components of pharmacological management of HF, such as angiotensin receptor-neprilysin inhibitor (ARNI), angiotensin-II receptor blockers, mineralocorticoid receptor antagonists, induced multidirectional changes in the level of apelin and NPs [31,32,33]. This evidence concerns the gene NR3C2 and hydrops fetalis.